Drugs / S44819
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02877615 | Dec 2016 → Mar 2019 | — | Servier | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S44819 | “BACKGROUND: S44819, a selective GABAA α5 receptor antagonist, reduces tonic post-ischaemic inhibition of the peri-infarct cortex.” PMID 32085836 ↗ Mar 2020 |
| Action | Inhibit | “BACKGROUND: S44819, a selective GABAA α5 receptor antagonist, reduces tonic post-ischaemic inhibition of the peri-infarct cortex.” PMID 32085836 ↗ Mar 2020 |
| Route | Oral | “Randomized Efficacy and Safety Trial With Oral S 44819 After Recent Ischemic Cerebral Event.” NCT02877615 ↗ |